CliffBio
small molecule

ZOLYMBUS

BIMATOPROST

Loss of exclusivityJune 2036latest FDA-listed patent expiry
CompanyThea →See this company's full patent-cliff portfolio

Drug detail

Brand nameZOLYMBUS
Active ingredientBIMATOPROST
Strength0.01%
Dosage formGEL
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalSeptember 2025
Marketing statusRX

Listed patents

PatentExpiresType
10314780June 2036product

Regulatory exclusivity

CodeExpires
NDFSeptember 2028

More from Thea

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.